Document:

Exhibit 4.1

 

EXHIBIT A

 

IVERIC
bio, Inc.

 

FORM OF WARRANT TO PURCHASE COMMON
STOCK

 

Number
of Shares: [     ] 

(subject to adjustment)

 

	Warrant No. [    ]	 	Original Issue Date: June [    ], 2020

 

IVERIC bio, Inc., a Delaware corporation (the “Company”),
hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or
its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [ ] shares of common stock, $0.001 par value per share (the “Common Stock”), of the
Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at
an exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in Section 9 herein, the
 “Exercise Price”) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase
Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to
time on or after the date hereof (the “Original Issue Date”) and through and including the date this Warrant
is exercised in full (the “Expiration Date”), subject to the following terms and conditions:

 

1.            Definitions.
For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)  “Affiliate”
means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used
in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.

 

(b)  “Commission”
means the United States Securities and Exchange Commission.

 

(c)  “Closing
Sale Price” means, for any security as of any date, the last trade price for such security on the Principal Trading
Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an
extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00
P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national
securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the
over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency
succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the
fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine
the fair market value. The Board of Directors’ determination shall be binding upon all parties absent demonstrable
error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or
other similar transaction during the applicable calculation period.

 

    A-1

     

    

 

(d)  “Marketable
Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to
the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the
 “Exchange Act”), and is then current in its filing of all required reports and other information under the Securities
Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder
in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing
thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter
market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly
re-selling all of the issuer’s shares and/or other securities that would be received by the Holder in such Fundamental Transaction
were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction.

 

(e)  “Principal
Trading Market” means the national securities exchange or other trading market on which the Common Stock is primarily
listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.

 

(f)  “Registration
Statement” means the Company’s Registration Statement on Form S-3 (File No. 333-226497), that became
effective on August 15, 2018.

 

(g)  “Securities
Act” means the Securities Act of 1933, as amended.

 

(h)  “Trading
Day” means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed
or admitted for trading, “Trading Day” means any day except any Saturday, any Sunday, any day which is a federal legal
holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other
governmental action to close.

 

(i)  “Transfer
Agent” means Computershare Trust Company, N.A., the Company’s transfer agent and registrar for the Common Stock,
and any successor appointed in such capacity.

 

    A-2

     

    

 

2.            Issuance
of Securities; Registration of Warrants. The Warrant, as initially issued by the Company, is offered and sold pursuant to
the Registration Statement. As of the Original Issue Date, the Warrant Shares are offered under the Registration Statement.
Accordingly, the Warrant and, assuming an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act
as in effect on the Original Issue Date, the Warrant Shares, are not “restricted securities” under
Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be
maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder
(which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder)
from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the
purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the
contrary.

 

3.            Registration
of Transfers. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent
to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment
for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially
the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred
shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance
by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant.
The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant
under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof
as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.

 

4.            Exercise
and Duration of Warrants.

 

(a)            All
or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time
and from time to time on or after the Original Issue Date and through and including the Expiration Date.

 

(b)            The
Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the
 “Exercise Notice”), completed and duly signed. The date on which such exercise notice is delivered to the Company
(as determined in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not
be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice
shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase
the remaining number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and
agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.

 

    A-3

     

    

 

5.            Delivery
of Warrant Shares.

 

(a)  Upon
exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise
Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant
to such exercise to the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”)
through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities
Transfer Program (the “FAST Program”) or if the certificates are required to bear a legend regarding restriction
on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate,
registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common
Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a “Person”)
so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares
as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date
of delivery of the certificates evidencing such Warrant Shares, as the case may be.

 

(b)  If by the close of the third (3rd)
Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number
of Warrant Shares in the manner required pursuant to Section 5(a) or fails to credit the Holder’s DTC account
for such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt
of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall, within three (3) Trading Days after the Holder’s request promptly honor its obligation to deliver
to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the
excess (if any) of Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock
so purchased in the Buy-In less the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the
Closing Sale Price of a share of Common Stock on the Exercise Date.

 

(c)  To
the extent permitted by law and subject to Section 5(b), the Company’s obligations to issue and deliver Warrant
Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are
absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent
with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or
any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection
with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder’s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates
representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    A-4

     

    

 

6.            Charges,
Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding
any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by
the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect
of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of
the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding
or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

 

7.            Replacement
of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon
receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case,
a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the
Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver
such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

 

8.            Reservation
of Warrant Shares. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available
out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it
to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable
and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of
persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that
all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance
with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such
action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which
the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder,
take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.

 

    A-5

     

    

 

9.            Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the “Number of
Warrant Shares”) are subject to adjustment from time to time as set forth in this Section 9.

 

(a)  Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its
Common Stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger
number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of
Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company,
then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number
of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of
Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution,
provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor,
the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the
Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment
pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such
subdivision or combination.

 

(b)  Pro
Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock
for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock
covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common
Stock), or (iv) cash or any other asset (in each case, a “Distribution”), other than a reclassification
as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined
for the participation in such Distribution; provided, however, to the extent that the Holder’s right to participate
in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for
the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder
exceeding the ownership limitation set forth in Section 11(a) hereof.

 

    A-6

     

    

 

(c)  Fundamental
Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of
the Company with or into another Person, in which the Company is not the surviving entity, (ii) the Company effects any sale
to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant
to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing
more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts
such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other
Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which
the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting
power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above)
(in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the Holder shall
have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would
have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii) above, assuming it had tendered, and
the offeror had accepted, such Warrant Shares) (the “Alternate Consideration”). The Company shall not effect
any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities
of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous “cashless
exercise” of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation
thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall
assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the
Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall
similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event
of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable
Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised
in full in a “cashless exercise” pursuant to Section 10 below effective immediately prior to and contingent upon
the consummation of such Fundamental Transaction.

 

(d)  Exercise
Price. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price
shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder
for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect
immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the
par value of the Common Stock then in effect.

 

(e)  Calculations.
All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as
applicable.

 

(f)  Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at
the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant
and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number
or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions
giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the
Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

    A-7

     

    

 

(g)  Notice
of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution
of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or
warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the
voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof
shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction
at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock
in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice
or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition,
if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder
approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of
Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information,
the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date
such Fundamental Transaction is consummated.

 

10.           Cashless
Exercise. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a “cashless
exercise.” Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities
effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:

 

X = Y [(A-B)/A]

 

where:

 

“X” equals the number of Warrant
Shares to be issued to the Holder;

 

“Y” equals the total number
of Warrant Shares with respect to which this Warrant is then being exercised;

 

“A” equals the Closing Sale
Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and

 

“B” equals the Exercise Price
per Warrant Share then in effect on the Exercise Date.

 

For purposes of Rule 144 promulgated under the Securities
Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise” transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment
is proper at the time of such exercise).

 

    A-8

     

    

 

In no event will the exercise of this Warrant be settled in
cash.

 

11.           Limitations
on Exercise.

 

(a)  Notwithstanding
anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall
not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which,
upon giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock
beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 9.99% (the
 “Maximum Percentage”) of the total number of issued and outstanding shares of Common Stock of the Company
following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the
Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the
Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 9.99% of the combined voting power of
all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining
the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as
reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, filed with the
Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice
by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request
of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to
the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not
in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the
sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate
number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other
Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of
Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this
Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder
and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the
Company that do not have voting power (including without limitation any securities of the Company which would entitle the
holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option,
warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles
the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the
limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose
beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of
the Exchange Act.

 

    A-9

     

    

 

(b)   This
Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order
to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction
as contemplated in Section 9(c) of this Warrant.

 

12.            No
Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the
next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any
such fractional shares.

 

13.            Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day or (ii) the next Trading Day after
the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day
or later than 5:30 P.M., New York City time, on any Trading Day. The e-mail addresses for such communications shall be:

 

If to the Company:

 

IVERIC bio, Inc. 

One Penn Plaza 

35th Floor 

New York, New York 10119 

Attention: General Counsel

 

Email: notices@ivericbio.com

 

If to the Holder, to its e-mail
address set forth herein or on the books and records of the Company.

 

Or, in each of the above instances, to such other address or
e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior
to the effectiveness of such change.

 

14.            Warrant
Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged
or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation
to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business
shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly
cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s
last address as shown on the Warrant Register.

 

    A-10

     

    

 

15.           Miscellaneous.

 

(a)   No
Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be
entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the
Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to
any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger,
amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise,
prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the
Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether
such liabilities are asserted by the Company or by creditors of the Company.

 

(b)  Authorized
Shares. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all
such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable
Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to
perform its obligations under this Warrant.

 

(c)  Successors
and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant
may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors
and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the
Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended
only in writing signed by the Company and the Holder, or their successors and assigns.

 

    A-11

     

    

 

(d)            Amendment
and Waiver. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with
the written consent of the Company and the Holder.

 

(e)            Acceptance.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

(f)            Governing
Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT
SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE
PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE
JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED
HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND
AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO
PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR
OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH
SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED
TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY
WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(g)            Headings.
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect
any of the provisions hereof.

 

(h)            Severability.
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and
the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable
substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    A-12

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	IVERIC bio, Inc.
	 	 
	 	By:  	 
	 	 	Name:
	 	 	Title:

 

    A-13

     

    

 

 

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

[To be executed by the Holder to purchase
shares of Common Stock under the Warrant]

 

Ladies and Gentlemen:

 

(1)            The
undersigned is the Holder of Warrant No. ___ (the “Warrant”) issued by IVERIC bio, Inc., a Delaware corporation
(the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant.

 

(2)            The
undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.

 

(3)            Pursuant
to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the
Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:

 

___________________________________

 

(4)            By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of
the Warrant to which this notice relates.

 

 

	Dated:	 	 
	 	 	 
	Name of Holder:	 	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

(Signature must conform in all respects
to name of Holder as specified on the face of the Warrant)

 

    A-14Exhibit 10.1

 

STOCK PURCHASE AGREEMENT

 

This STOCK PURCHASE AGREEMENT (this “Agreement”)
is dated as of June 17, 2020, by and between IVERIC bio, Inc., a Delaware corporation (the “Company”),
and the Persons set forth on Schedule 1 of this Agreement (together with their successors and assigns, the “Purchasers”
and, together with the Company, the “Parties”).

 

W I T N E S S E T H:

 

WHEREAS, the Company and the Purchasers
are executing and delivering this Agreement in a private placement (the “Private Placement”) pursuant to Section
4(a)(2) of and/or Regulation D (as defined below) under the Securities Act (as defined below);

 

WHEREAS, pursuant to the terms and subject
to the conditions set forth in this Agreement, the Company wishes to sell to the Purchasers shares of Common Stock (the “Shares”)
for an aggregate purchase price of $35,462,767 (the “Aggregate Purchase Price”);

 

WHEREAS, the Purchasers desire to purchase
the Shares from the Company; and

 

WHEREAS, the Company
is concurrently initiating an underwritten public offering of Common Stock (the “Public Offering”) pursuant
to the Company’s registration statement on Form S-3 (File No. 333-226497).

 

NOW, THEREFORE, in consideration of the
mutual covenants and agreements set forth herein, the Parties agree as follows:

 

ARTICLE 1

DEFINITIONS

 

Section 1.1          
General Definitions. Wherever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context
otherwise requires, the following terms have the following meanings:

 

“Affiliate” means any
Person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect
to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment manager
as such Purchaser will be deemed to be an Affiliate of such Purchaser. As used in this definition of “Affiliate,” the
term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of
the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest,
by contract, or otherwise.

 

“Aggregate Cap Amount”
shall have the meaning set forth in Section 2.1 of this Agreement.

 

“Aggregate Purchase Price”
shall have the meaning set forth in the recitals.

 

     

     

    

 

“Agreement” shall have
the meaning set forth in the introductory paragraph.

 

“Applicable Laws” means
all laws, statutes, rules and regulations of Governmental Authorities in the United States or elsewhere applicable to, as the context
may require, the Company and its Subsidiaries or the relevant Purchaser.

 

“BSA” shall have the
meaning set forth in Section 3.2(n).

 

“BSA/PATRIOT Act” shall
have the meaning set forth in Section 3.2(n).

 

“Business Day” means
any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or required by law,
regulation or executive order to close or be closed.

 

“Closing” shall have
the meaning set forth in Section 2.2 of this Agreement.

 

“Closing Date” shall
have the meaning set forth in Section 2.2 of this Agreement.

 

“Commission” means the
United States Securities and Exchange Commission.

 

“Common Stock” means
the common stock, $0.001 par value per share, of the Company.

 

“Company” shall have
the meaning set forth in the introductory paragraph.

 

“Cut Back Shares” shall
have the meaning set forth in Section 4.1(c) of this Agreement.

 

“Dollars” and the “$”
sign mean the lawful currency of the United States of America.

 

“Effective Date” shall
have the meaning set forth in Section 4.6(b).

 

“Effectiveness Period”
shall have the meaning set forth in Section 4.1(b).

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.

 

“Filing Failure” shall
have the meaning set forth in Section 4.5(a).

 

“Form 8-K” shall have
the meaning set forth in Section 6.16.

 

“Governmental Authority”
means any government, governmental department, ministry, cabinet, commission, board, bureau, agency, tribunal, regulatory authority,
instrumentality, judicial, legislative, fiscal, or administrative body or entity, whether domestic or foreign, federal, state or
local, having jurisdiction over the matter or matters and Person or Persons in question.

 

“Investment Company Act”
means the Investment Company Act of 1940, as amended, including the rules and regulations promulgated thereunder.

 

“Investor Questionnaire”
shall have the meaning set forth in Section 3.2(k).

 

    2

     

    

 

“Knowledge” means, with
respect to the Company, the actual knowledge of any executive officer of the Company.

 

“Material Adverse Effect”
means a material adverse effect on (i) the financial condition, operating results, assets, liabilities, operations or business
of the Company and its Subsidiaries, taken as a whole, or (ii) the ability of the Company to perform any of its material obligations
under this Agreement.

 

“Material Contract” means
any contract of the Company that has been filed or was required to have been filed, pursuant to Item 601(b)(4) or Item 601(b)(10)
of Regulation S-K, as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 or any
subsequent SEC Report filed or required to be filed by the Company.

 

“Non-Public Information”
shall have the meaning set forth in Section 6.17.

 

“OFAC” shall have the
meaning set forth in Section 3.2(n).

 

“OFAC List” shall have
the meaning set forth in Section 3.2(n).

 

“Organizational Documents”
means the Certificate of Incorporation and Bylaws, each as amended to date, of the Company.

 

“Parties” shall have
the meaning set forth in the introductory paragraph.

 

“PATRIOT Act” shall have
the meaning set forth in Section 3.2(n).

 

“Permitted
Transferee” means, with respect to a Purchaser, an Affiliate of such Purchaser that is an investment fund or managed
account that shares the same management company or investment adviser with such Purchaser.

 

“Person” means and includes
any natural person, individual, partnership, joint venture, corporation, trust, limited liability company, limited company, joint
stock company, unincorporated organization, Governmental Authority or any political subdivision or agency thereof, or any other
entity.

 

“Placement Agents” shall
have the meaning set forth in Section 3.1(o).

 

“Press Release” shall
have the meaning set forth in Section 6.16.

 

“Private Placement” shall
have the meaning set forth in the recitals.

 

“Prospectus” means (i) the
prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments
and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus,
and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act.

 

    3

     

    

 

“Public Offering”
shall have the meaning set forth in the recitals.

 

“Public Offering
Price” shall have the meaning set forth in Section 2.1.

 

“Purchasers” shall have
the meaning set forth in the introductory paragraph.

 

“Preliminary
Public Offering Prospectus” means the preliminary prospectus supplement relating to the Public Offering dated the date
hereof.

 

“Public Offering
Prospectus” means the final prospectus supplement relating to the Public Offering.

 

“Purchase
Price” shall have the meaning set forth in Section 2.1.

 

“QIB”
shall have the meaning set forth in Section 3.2(k).

 

“Registrable Securities”
means (i) the Shares and (ii) any other securities issued or issuable with respect to or in exchange for Shares, whether by
merger, charter amendment or otherwise; provided that a security shall cease to be a Registrable Security upon the earliest
of (A) a sale pursuant to a Registration Statement or a valid exemption under the Securities Act, and (B) such security
becoming eligible for sale without restriction by the Purchasers or their Permitted Transferees pursuant to Rule 144 and without
the requirement to be in compliance with Rule 144(c)(1) (or any successor thereto) promulgated under the Securities Act.

 

“Registration Liquidated Damages”
shall have the meaning set forth in Section 4.5(a).

 

“Registration Statement”
means a registration statement on Form S-3 (unless the Company is not then eligible to register for resale the Common Stock on
such registration statement, in which case registration shall be on another appropriate form for such purpose) in satisfaction
of the requirements set forth in Section 4.1 and covering the resale of the Registrable Securities.

 

“Regulation D” means
Regulation D promulgated under the Securities Act.

 

“Regulation S” means
Regulation S promulgated under the Securities Act.

 

“Rule 144A” means Rule
144A promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar
rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“SEC Reports” shall have
the meaning set forth in Section 3.1(a) of this Agreement.

 

“Securities Act” means
the Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.

 

“SEC Restrictions” shall
have the meaning set forth in Section 4.1(c) of this Agreement.

 

    4

     

    

 

“Selling Securityholder
Questionnaire” means a form of selling securityholder questionnaire as may be reasonably requested by the Company from
time to time.

 

“Shares” shall have the
meaning set forth in the recitals.

 

“Subsidiary” or “Subsidiaries”
means any entity of which securities or other ownership interests having ordinary voting power to elect a majority of the board
of directors or other Persons performing similar functions are at the time directly or indirectly owned or controlled by Company.

 

“Transfer Agent” shall
have the meaning set forth in Section 4.6(a) of this Agreement.

 

Section 1.2          
Interpretation. In this Agreement, unless the context otherwise requires, all words and personal pronouns relating thereto
shall be read and construed as the number and gender of the party or parties requires and the verb shall be read and construed
as agreeing with the required word and pronoun; the division of this Agreement into Articles and Sections and the use of headings
and captions is for convenience of reference only and shall not modify or affect the interpretation or construction of this Agreement
or any of its provisions; the words “herein,” “hereof,” “hereunder,” “hereinafter”
and “hereto” and words of similar import refer to this Agreement as a whole and not to any particular Article or Section
hereof; the words “include,” “including,” and derivations thereof shall be deemed to have the phrase “without
limitation” attached thereto unless otherwise expressly stated; references to a specified Article, Exhibit, Section or Schedule
shall be construed as a reference to that specified Article, Exhibit, Section or Schedule of this Agreement; and any reference
to this Agreement means such document as the same shall be amended, supplemented or modified and from time to time in effect.

 

ARTICLE 2

AGREEMENT FOR THE PURCHASE OF THE SHARES

 

Section 2.1          
Purchase and Sale of the Shares. Subject to the conditions set forth in Article 5 of this Agreement, each Purchaser
shall purchase at the Closing and the Company shall issue and sell at the Closing to each Purchaser such number of Shares equal
to the aggregate dollar amount as set forth opposite such Purchaser’s name on Schedule 1 hereto (the “Purchase
Price”) divided by the per share price to the public in the Public Offering (the “Public Offering Price”),
as set forth on the cover page of the Public Offering Prospectus; provided, however, that (a) no fractional number
of Shares shall be sold hereunder, (b) any fractional number of Shares shall be rounded down to the nearest whole number of Shares
and (c) the Aggregate Purchase Price will be reduced by the value of any fractional share (as calculated on the basis of the Public
Offering Price); provided further, that if the Public Offering Price is less than the “minimum price” as defined
in Nasdaq Listing Rule 5635(d) and the aggregate number of Shares to be issued to the Purchasers pursuant to the foregoing calculation
shall exceed 19.99% of the issued and outstanding Common Stock immediately prior to the Closing Date (the “Aggregate Cap
Amount”), then the aggregate number of Shares to be issued to the Purchasers shall be reduced to equal the Aggregate
Cap Amount and each Purchaser shall be issued its pro rata portion of such Aggregate Cap Amount and the Purchase Price to be paid
by such Purchaser shall be reduced by a corresponding amount. Each Purchaser shall severally, and not jointly, be liable for only
the purchase of Shares in accordance with this Section 2.1 and not for the purchase of Shares for any other Purchaser. The
Company’s agreement with each of the Purchasers is a separate agreement and the sale of Shares to each of the Purchasers
is a separate sale. The obligations of each Purchaser hereunder are expressly not conditioned on the purchase by any or all of
the other Purchasers of the Shares such other Purchasers have agreed to purchase.

 

    5

     

    

 

Section 2.2          
Closing; Delivery. The closing of the purchase and sale of the Shares hereunder (the “Closing”) shall
take place remotely via the exchange of documents and signatures at 10:00 a.m. New York City time on June 22, 2020, or at such
other time as soon as practicable thereafter as mutually agreed by the Parties (the “Closing Date”). At the
Closing, the Company shall deliver, or cause to be delivered, to each Purchaser a certificate, instrument or book entry representing
the Shares being purchased by such Purchaser, and each Purchaser shall deliver, or cause to be delivered, the Purchase Price by
wire transfer of immediately available funds in Dollars to an account designated by the Company.

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

 

Section 3.1          
Representations and Warranties of the Company. Assuming the accuracy of the representations and warranties of the Purchasers
set forth in Section 3.2 and except as set forth in the SEC Reports (as defined below), which disclosures serve to qualify
these representations and warranties in their entirety, the Company hereby represents and warrants as of the date of this Agreement
and as of the Closing Date that:

 

(a)              
Since January 1, 2020, the Company has timely filed all required reports (including exhibits), and any required amendments
to any of the foregoing, with the Commission (such reports and amendments, together with the Preliminary Public Offering Prospectus,
collectively, the “SEC Reports”). As of their respective filing dates, each of the SEC Reports complied in all
material respects with the requirements of the Exchange Act and no SEC Reports, when filed, declared effective or mailed, as applicable,
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(b)              
The Company and each of its Subsidiaries has been duly organized, is validly existing and in good standing under the laws
of their respective jurisdictions of organization, has the corporate power and authority to own or lease its property and to conduct
its business and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its
business or its ownership or leasing of property requires such qualification, except to the extent that the failure to so qualify
or be in good standing would not result in a Material Adverse Effect.

 

(c)              
This Agreement has been duly authorized by the Company and, when duly executed and delivered in accordance with its terms
by the Parties, will constitute a valid and legally binding agreement of the Company, enforceable against the Company in accordance
with its terms, except as such enforceability may be limited by (i) applicable insolvency, bankruptcy, reorganization, moratorium
or other similar laws affecting the enforcement of creditors’ rights generally, (ii) applicable equitable principles
relating to enforceability (whether considered in a proceeding at law or in equity), or (iii) with regard to any indemnity or contribution
provision, federal or state securities laws or considerations of public policy.

 

    6

     

    

 

(d)              
The authorized capital stock of the Company conforms in all material respects as to legal matters to the description thereof
contained in the SEC Reports.

 

(e)              
The Shares have been duly and validly authorized and, when issued in accordance with the terms of this Agreement against
payment by the Purchasers therefor, will be validly issued, fully paid and non-assessable, and the issuance of the Shares will
not be subject to any preemptive or similar rights that have not been validly waived.

 

(f)               
The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement
will not contravene (i) any Organizational Documents of the Company, (ii) any Material Contract, or (iii) any judgment,
order or decree of any Governmental Authority having jurisdiction over the Company or any of its Subsidiaries, except in the cases
of the foregoing clauses (ii) and (iii) any such contravention that would not, individually or in the aggregate, have a Material
Adverse Effect. No consent, approval, authorization or order of, or qualification with, any Governmental Authority is required
for the performance by the Company of its obligations under this Agreement, except those that have already been obtained or made
or as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares,
or the filing with the Commission of one or more Registration Statements pursuant to, and in accordance with, Section 4.1,
and except for those the absence of which would not, individually or in the aggregate, have a Material Adverse Effect. The Company
is not in violation of its Organizational Documents.

 

(g)              
Since December 31, 2019, there have not been any changes, conditions, events or circumstances which have had, or would reasonably
be expected to have, a Material Adverse Effect.

 

(h)              
The Company is not, and immediately after issuance of the Shares will not be, an “investment company” within
the meaning of the Investment Company Act.

 

(i)                
Since December 31, 2019, (i) the Company has not incurred any material liability or obligation, direct or contingent, nor
entered into any material transaction other than those in the ordinary course of business and except as contemplated in this Agreement
and in connection with the Public Offering; (ii) the Company has not purchased any of its outstanding capital stock, nor declared,
paid or otherwise made any dividend or distribution of any kind on its capital stock; and (iii) there has not been any material
change in the Company’s capital stock (other than options or equity awards granted under the Company’s equity incentive
plans or in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to the acceptance of an offer of employment
or issuances of Common Stock pursuant to the Company’s employee stock purchase plan), or the short-term debt or long-term
debt of the Company, except in each case as otherwise made in the ordinary course of business of the Company.

 

    7

     

    

 

(j)                
The Company and its Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting
Language included in the SEC Reports is accurate. Since the end of the Company’s most recent audited fiscal year, there has
been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and
(2) no change in the Company’s internal control over financial reporting that has materially and adversely affected, or is
reasonably likely to materially and adversely affect, the Company’s internal control over financial reporting. The Company
and its Subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 of the Exchange
Act) that has been designed to ensure that information required to be disclosed by the Company in the SEC Reports is recorded,
processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls
and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate
to allow timely decisions regarding required disclosure.

 

(k)              
Except in connection with the Public Offering, the Company has not sold, issued or distributed any shares of Common Stock
during the six-month period preceding the Closing Date, including any sales pursuant to (i) Rule 144A, (ii) Regulation D or
(iii) Regulation S, other than shares of Common Stock issued pursuant to (1) the Company’s employee benefit plans, employee
stock purchase plan, qualified stock option plans or other employee compensation plans, (2) any award granted in accordance with
Nasdaq Listing Rule 5635(c)(4) as a material inducement to the acceptance of an offer of employment, or (4) the exercise of outstanding
options, warrants or similar rights or the vesting of restricted stock awards.

 

(l)                
Assuming the accuracy of the representations and warranties of the Purchasers set forth in Section 3.2 of this Agreement
and their compliance with their agreements set forth therein, (i) the Shares will be issued in compliance with all applicable federal
and state securities laws, and (ii) it is not necessary, in connection with the issuance and sale of the Shares to the Purchasers,
to register the Shares under the Securities Act.

 

(m)            
Neither the Company nor any of its Affiliates has, directly or through any agent, sold, offered for sale, solicited offers
to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be integrated with
the sale of the Shares in a manner that would require registration of the Shares under the Securities Act.

 

(n)              
None of the Company or any of its Affiliates or any other Person acting on its or their behalf has (i) solicited offers
for, or offered or sold, the Shares by means of any form of general solicitation or general advertising within the meaning of Rule
502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act
or (ii) engaged in any directed selling efforts within the meaning of Regulation S, and all such Persons have complied with the
offering restrictions requirement of Regulation S.

 

    8

     

    

 

(o)              
There is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s fee
or other similar fee or commission as a result of the issuance and sale of the Shares in accordance with and as contemplated by
this Agreement, other than the underwriters engaged by the Company with respect to the Public Offering and Cowen and Company, LLC
and Credit Suisse Securities (USA) LLC as the placement agents engaged by the Company with respect to the Private Placement (together,
the “Placement Agents”).

 

(p)              
The Company is not an “ineligible issuer” (as defined in Rule 405 of the Securities Act).

 

(q)              
The Company acknowledges that each of the Purchasers will rely upon the truth and accuracy of, and the compliance with,
the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.

 

Section 3.2          
Representations and Warranties of the Purchasers. Each Purchaser, severally and not jointly, hereby represents and warrants
on behalf of itself to the Company as of the date of this Agreement and as of the Closing Date that:

 

(a)              
Such Purchaser, if an entity, is duly organized, in good standing and validly existing under the laws of the jurisdiction
of organization.

 

(b)              
The Agreement has been duly authorized, executed and delivered by such Purchaser and constitutes the valid and legally binding
obligation of such Purchaser, enforceable against such Purchaser in accordance with its terms, except as such enforceability may
be limited by (i) applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting the enforcement
of creditors’ rights generally, (ii) applicable equitable principles relating to enforceability (whether considered in a
proceeding at law or in equity), or (iii) with regard to any indemnity or contribution provision, federal or state securities laws
or considerations of public policy.

 

(c)              
Such Purchaser has full power and authority to purchase the Shares being purchased by the Purchaser and to enter into and
perform its other obligations under the Agreement and carry out the other transactions contemplated thereby.

 

(d)              
The Shares to be received by such Purchaser hereunder will be acquired for such Purchaser’s own account, and not with
a view to the resale or distribution of any part thereof in violation of the Securities Act, and such Purchaser has no agreement
or understanding, directly or indirectly, or present intention of selling, granting any participation in, or otherwise distributing
such Shares in violation of applicable federal and state securities laws. Such Purchaser has no present intent to effect a “change
of control” of the Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the Exchange
Act, and such Purchaser’s and its Affiliates’ beneficial ownership of Common Stock will not exceed 9.99% of the outstanding
Common Stock immediately following the Closing.

 

(e)              
Such Purchaser can bear the economic risk and complete loss of its investment in the Shares and has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.

 

    9

     

    

 

(f)               
Such Purchaser understands that the Shares are characterized as “restricted securities” under the U.S. federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that
under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in
certain limited circumstances.

 

(g)              
Such Purchaser understands that the Shares are being offered and sold to it in reliance on specific exemptions from the
registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth
and accuracy of, and such Purchasers’ compliance with, the representations, warranties, agreements, acknowledgments and understandings
of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser
to acquire the Shares.

 

(h)              
Such Purchaser understands that any certificates, instruments, or book entries may be notated with one or all of the following
legends:

 

(i)                
“THESE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL (WHICH COUNSEL SHALL BE REASONABLY SATISFACTORY TO THE COMPANY) THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS
SOLD PURSUANT TO RULE 144 OF THE SECURITIES ACT.”

 

(ii)             
Any legend required by the Applicable Laws of any state or other jurisdiction to the extent such laws are applicable to
the Shares represented by the certificate, instrument, or book entry so legended.

 

(i)                
Such Purchaser has (i) received (or otherwise had made available to it by the filing by the Company of an electronic version
thereof with the Commission) all the information from the Company and its management that the Purchaser considers necessary or
appropriate for deciding whether to purchase the Shares hereunder, including the SEC Reports and (ii) had an opportunity to ask
questions and receive answers from the Company regarding the Company, its financial condition, results of operations and prospects,
and the terms and conditions of the offering of the Shares sufficient to enable it to evaluate its investment; provided
that the foregoing does not limit or modify the representations and warranties made by the Company in Section 3.1 of this
Agreement or the right of each of the Purchasers to rely thereon.

 

(j)                
Such Purchaser did not learn of the offering and sale of the Shares as a result of any general solicitation or general advertising.

 

    10

     

    

 

 

(k)           Such Purchaser (i) is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect
to, investments in securities presenting an investment decision like that involved in the purchase of the Shares, including investments
in comparable companies, and (ii) is an “accredited investor” as such term is defined in Regulation D and either
qualifies as (A) an institutional “accredited investor” described in Rule 501(a)(1), (2), (3) or (7) under the Securities
Act or (B) a “qualified institutional buyer” (“QIB”) as such term is defined in Rule 144A under
the Securities Act or an entity comprised exclusively of QIBs. Such Purchaser has executed and delivered to the Company a questionnaire
in substantially the form attached hereto as Exhibit B (the “Investor Questionnaire”), which such Purchaser
represents and warrants is true, correct and complete. Such Purchaser has not taken any of the actions set forth in, and is not
subject to, the disqualification provisions of Rule 506(d)(1) of the Securities Act.

 

(l)            Such Purchaser understands that nothing in this Agreement or any other materials presented to the Purchaser in connection
with the purchase and sale of the Shares constitutes legal, tax or investment advice. Such Purchaser has consulted such legal,
tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase
of the Shares.

 

(m)          Since the date on which the Company or its representatives first engaged in discussions with the Purchaser about the sale
of the securities contemplated by this Agreement until the transactions contemplated by this Agreement are first publicly disclosed
by the Company, such Purchaser has not and will not directly or indirectly, nor has or will any person acting on behalf of or pursuant
to any understanding with each Purchaser, disclosed or disclose any information regarding the transactions contemplated hereby
to any third parties (other than such Purchaser’s legal, accounting and other advisors to whom such information may have
been disclosed on a confidential and “need to know” basis) or directly or indirectly engaged or engage in, or caused
or cause any person to engage in, any transactions in or relating to the securities of the Company (including, without limitation,
any short sales (as defined in Rule 200(a) of Regulation SHO) or hedging transactions involving or relating to the Company’s
securities). Until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, such Purchaser
will maintain the confidentiality of all disclosures made to it in connection with this transaction, including the existence and
terms of this transaction, other than disclosures to such Purchaser’s legal, accounting and other advisors to whom any such
information may have been disclosed on a confidential and “need to know” basis. Each Purchaser understands and acknowledges
that the Commission currently takes the position that coverage of short sales of shares of the Common Stock “against the
box” prior to effectiveness of a resale registration statement with securities included in such registration statement would
be a violation of Section 5 of the Securities Act, as set forth in Item 239.10 of the Securities Act Rules Compliance and Disclosure
Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance.

 

    11

     

    

 

(n)          Such Purchaser is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered
by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or in any executive order
issued by the President of the United States and administered by OFAC (“OFAC List”), or a person or entity targeted
by any OFAC sanctions program, (ii) an entity owned fifty percent (50%) or more, directly or indirectly, by one or more persons
or entities on the OFAC List, (iii) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515,
or (iv) a non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell bank. Such Purchaser agrees to provide
law enforcement agencies, if requested thereby, such records as required by applicable law, provided that the Purchaser
is permitted to do so under applicable law. If the Purchaser is a financial institution subject to the Bank Secrecy Act (31 U.S.C.
Section 5311 et seq.) (the “BSA”), as amended by the USA PATRIOT Act of 2001 (the “PATRIOT Act”),
and its implementing regulations (collectively, the “BSA/PATRIOT Act”), the Purchaser maintains policies and
procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. To the extent required, the Purchaser
maintains policies and procedures reasonably designed for the screening of its investors against the OFAC sanctions programs, including
the OFAC List. The Purchaser maintains policies and procedures reasonably designed to ensure that the funds held by the Purchaser
and used to purchase the Shares were legally derived. The Purchaser agrees that, at or prior to the Closing, such Purchaser shall
deliver to the Company a duly completed and executed Internal Revenue Service Form W-9 or Internal Revenue Service Form W-8BEN-E,
as applicable.

 

(o)          Such Purchaser has access to cash in an amount sufficient to pay to the Company the purchase price as set forth opposite
such Purchaser’s name on Schedule 1 hereto.

 

(p)          Such Purchaser acknowledges that the Company and the Placement Agents will rely upon the truth and accuracy of, and the
compliance with, the representations, warranties, agreements, acknowledgements and understandings of such Purchaser set forth herein.

 

(q)          There is no broker, investment banker, financial advisor, finder or other person which has been retained by or is authorized
to act on behalf of such Purchaser who might be entitled to any fee or commission for which the Company will be liable in connection
with the execution of this Agreement and the consummation of the transactions contemplated hereby.

 

(r)           Such Person is not relying and has not relied on any representations or warranties whatsoever regarding the Company, express
or implied, except for the representations and warranties in Section 3.1.  Such representations and warranties by the
Company constitute the sole and exclusive representations and warranties of the Company.  In connection with the due diligence
investigation of the Company by Purchaser, Purchaser and its Affiliates, directors, officers, employees, agents, representatives
and advisors have received and may continue to receive after the date hereof from the Company and its Affiliates, directors, officers,
employees, consultants, agents, representatives and advisors certain information regarding the Company.  Accordingly, Purchaser
hereby acknowledges and agrees that neither the Company nor any of its Affiliates, directors, officers, employees, consultants,
agents, representatives or advisors, nor any other Person, has made or is making any express or implied representation or warranty
with respect to such information unless any such information is expressly addressed or included in a representation or warranty
made by the Company contained in this Agreement. In addition, such Purchaser hereby acknowledges and agrees that it has not relied
upon the Placement Agents in connection with such Purchaser’s due diligence review of the Private Placement and the Company.

 

    12

     

    

 

ARTICLE 4

REGISTRATION RIGHTS

 

Section 4.1          
Mandatory Registration Statement.

 

(a)           Registration Statement. Subject to the terms and conditions of this Agreement, the Company shall use commercially
reasonable efforts to file a Registration Statement with the Commission on or before the date that is 60 days following the Closing
Date (the “Filing Date”) to register all of the Registrable Shares on Form S-3 under the Securities Act. The
Company shall use its commercially reasonable efforts to cause such Registration Statement to be declared effective within 90 days
following the Closing Date (or, in the event the Staff reviews and has written comments to the Registration Statement, within 120
days following the Closing Date), such efforts to include, without limiting the generality of the foregoing, preparing and filing
with the Commission any financial statements or other information that is required to be filed prior to the effectiveness of such
Registration Statement. Such Registration Statement shall not include any shares of Common Stock or other securities for the account
of any other holder without the prior written consent of a majority of the Registrable Securities then held by the Purchasers or
Permitted Transferees.

 

(b)           Filing; Effectiveness. The Company shall use its commercially reasonable efforts to keep the Registration Statement
continuously effective under the Securities Act for a period up to the earlier of (i) one year from the date of this Agreement
and (ii) the date that all Registrable Securities covered by such Registration Statement have been sold or can be sold without
restriction pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1) (or any successor thereto)
promulgated under the Securities Act (the “Effectiveness Period”). The Company shall notify the Purchasers in
writing promptly (and in any event within five (5) Business Days) after receiving notification from the Commission that a Registration
Statement has been declared effective or that a Prospectus has been filed.

 

(c)           Rule 415; Cutback. If at any time the Commission takes the position that the offering of some or all of the
Registrable Securities in the Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions
of Rule 415 under the Securities Act or requires any Purchaser to be named as an “underwriter,” the Company shall
use commercially reasonable efforts to persuade the Commission that the offering contemplated by such Registration Statement is
a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that
none of the Purchasers is an “underwriter.” In the event that, despite the Company’s commercially reasonable
efforts and compliance with the terms of this Section 4.1(c), the Commission does not alter its position, the Company
shall (i) remove from such Registration Statement such portion of the Registrable Securities (the “Cut Back Shares”)
and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the
Commission may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC
Restrictions”); provided, however, that the Company shall not agree to name any Purchaser as an “underwriter”
in such Registration Statement without the prior written consent of such Purchaser. Any cut-back imposed on the Purchasers pursuant
to this Section 4.1(c) shall be allocated among the Purchasers on a pro rata basis and shall be applied first to any
of the Registrable Securities of such Purchasers as such Purchasers shall designate, unless the SEC Restrictions require or provide
otherwise or the Purchasers otherwise agree. From and after such date as the Company is able to effect the registration of such
Cut Back Shares, the Company shall use commercially reasonable efforts to file a Registration Statement relating to such Cut Back
Shares and to have such Registration Statement declared effective by the Commission.

 

    13

     

    

 

Notwithstanding the foregoing, it is understood
and agreed that a registration statement under the Securities Act may expire pursuant to the rules and regulations of the Commission
after a specified date (currently, in the case of a shelf registration statement pursuant to Rule 415 under the Securities Act,
three years following the date it is declared effective by the Commission). It is agreed that any expiration of a registration
statement pursuant to the rules and regulations of the Commission shall not represent a violation or breach of any of the Company’s
obligations under this Agreement; provided that in such case, either prior to or promptly following such expiration time,
during the Effectiveness Period, the Company agrees to use commercially reasonable efforts to prepare, file and caused to be declared
effective a replacement Registration Statement.

 

Section 4.2          
Obligations of the Purchasers.

 

(a)           It shall be a condition precedent to the obligations of the Company to take any action pursuant to Sections 4.1(a)
through 4.1(c) with respect to the Registrable Securities of any Purchaser that such Purchaser furnish in writing to the
Company a Selling Securityholder Questionnaire and any other information regarding itself, the Registrable Securities held by it
and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the
registration of such Registrable Securities, and such Purchaser shall execute such documents in connection with such registration
as the Company may reasonably request. At least five (5) Business Days prior to the first anticipated filing date of any Registration
Statement, the Company shall notify each Purchaser of the information the Company requires from such Purchaser. A Purchaser shall
provide such information to the Company at least two (2) Business Days prior to the first anticipated filing date of such
Registration Statement.

 

(b)           Each Purchaser, by its acceptance of the Shares, agrees to cooperate with the Company, promptly furnish information to the
Company and complete and execute such documents in connection with the preparation and filing of a Registration Statement hereunder
unless such Purchaser has notified the Company in writing of its election to exclude all of its Registrable Securities from such
Registration Statement.

 

(c)           Each Purchaser agrees that, upon receipt of any notice from the Company of the happening of an event pursuant to Section 4.3(b),
such Purchaser will immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering
such Registrable Securities, until the Purchaser is advised by the Company that such dispositions may again be made. Each Purchaser
further agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it or an exemption
therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement and that it shall sell its
Shares in accordance with the Plan of Distribution set forth in the Prospectus. The Company may provide appropriate stop orders
to enforce the provisions of this paragraph.

 

    14

     

    

 

Section 4.3          
Registration Procedures. In connection with the Company’s registration obligations hereunder, the Company shall
(from the Filing Date and to the expiration of the Effectiveness Period):

 

(a)           Prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement
and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective,
as to the applicable Registrable Securities for the Effectiveness Period and comply in all material respects with the provisions
of the Securities Act and the Exchange Act applicable to the Company with respect to the disposition of all Registrable Securities
covered by the Registration Statement during the Effectiveness Period.

 

(b)           Promptly notify the Purchasers, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the
happening of any event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any
material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing, and promptly prepare, file with the Commission and furnish to such holder a supplement to or an amendment of such
Prospectus as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing;

 

(c)           Use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness
of any Registration Statement and, (ii) if such order is issued, obtain the withdrawal of any such order at the earliest practical
moment;

 

(d)           If requested by any Purchaser, promptly provide such Purchaser, without charge, one (1) copy of any Registration Statement
and any amendment thereto, each preliminary prospectus and Prospectus and each amendment or supplement thereto, and, if requested
by a Purchaser, each letter written by or on behalf of the Company to the Commission or the staff of the Commission and each item
of correspondence from the Commission or the staff of the Commission, in each case relating to such Registration Statement (other
than any portion of any of the foregoing which contains information for which the Company has sought confidential treatment), and
(ii) such number of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto
and such other documents as each Purchaser may reasonably request in order to facilitate the disposition of the Registrable Securities
owned by such Purchasers that are covered by such Registration Statement;

 

(e)           Prior to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify or cooperate
with the Purchasers and their counsel in connection with the registration or qualification of such Registrable Securities covered
by such Registration Statement for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested
by the Purchasers; provided, however, that the Company shall not be required in connection therewith or as a condition thereto
to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 4.3(e),
(ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 4.3(e),
or (iii) file a general consent to service of process in any such jurisdiction.

 

    15

     

    

 

(f)           The Company shall promptly inform the Purchasers in writing if, at any time during the Effectiveness Period, the Company
does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Purchasers are required to make available a
Prospectus in connection with any disposition of Shares.

 

Section 4.4          
Registration Expenses. The Company will pay all expenses incurred by it in complying with its obligations under Article
4, including filing and printing fees, fees and expenses of the Company’s counsel and accountants, costs associated with
clearing the Registrable Securities for sale under applicable state securities laws and listing fees, but excluding discounts,
commissions or fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect
to the Registrable Securities being sold, stock transfer taxes applicable to the sale of the Registrable Securities and fees and
disbursements of counsel for Purchasers.

 

Section 4.5          
Effect of Failure to Timely File the Registration Statement.

 

(a)           If a Registration Statement covering all of the Registrable Securities required to be covered thereby and required to be
filed by the Company pursuant to this Agreement is not filed with the Commission on or before the Filing Date (the “Filing
Failure”), the Company will make pro rata payments to each Purchaser then holding Registrable Securities, as liquidated
damages and not as a penalty (the “Registration Liquidated Damages”), an amount in cash equal to one percent
(1.0%) of the aggregate purchase price paid pursuant to this Agreement by such Purchaser for such Purchaser’s Registrable
Shares then held by such Purchaser and to be included in the Registration Statement on the Filing Date for the initial day of failure
to file such Registration Statement by the Filing Date and for each subsequent thirty (30)-day period (pro rata for any portion
thereof) thereafter for which no such Registration Statement is filed with respect to the Registrable Securities. Such payments
shall be made to each Purchaser then holding Registrable Securities in cash no later than ten (10) Business Days after the date
of the initial failure to file such Registration Statement by the Filing Deadline and after the end of each subsequent thirty (30)-day
period, as applicable.

 

(b)           The Parties agree that (i) notwithstanding anything to the contrary herein, no Registration Liquidated Damages shall be
payable with respect to any period after the expiration of the Effectiveness Period (it being understood that this sentence shall
not relieve the Company of any Registration Liquidated Damages accruing prior to the expiration of the Effectiveness Period) and
(ii) any Registration Liquidated Damages paid to a Purchaser shall be such Purchaser’s exclusive monetary remedy with respect
to the Company’s failure to file a Registration Statement in accordance with the terms set forth in this Agreement, but shall
not affect any other remedies available in equity.

 

(c)           Notwithstanding any other provision in this Agreement, (i) the Filing Date shall be extended and any Filing Failure shall
be automatically waived by no action of the Purchasers, in each case, without default by or liquidated damages payable by the Company
hereunder in the event that the Company’s failure to make such filing results from the failure of a Purchaser to timely provide
the Company with information requested by the Company and necessary to complete a Registration Statement in accordance with the
requirements of the Securities Act (in which case any such deadline would be extended, and a Filing Failure waived, with respect
to all Registrable Securities until such time as the Purchaser provides such requested information).

 

    16

     

    

 

Section 4.6          
Removal of Legends.

 

(a)           In connection with any sale, assignment, transfer or other disposition of the Shares by a Purchaser pursuant to Rule 144
or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance
by the Purchaser with the requirements of this Agreement, if requested by the Purchaser, the Company shall cause the transfer agent
for the Common Stock (the “Transfer Agent”) to remove any restrictive legends related to the book entry account
holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends
within two (2) Business Days of any such request therefor from such Purchaser, provided that the Company has timely received from
the Purchaser customary representations and other documentation reasonably acceptable to the Company in connection therewith.

 

(b)           Subject to receipt from the Purchaser by the Company and the Transfer Agent of customary representations and other documentation
reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares
(i) have been sold or transferred pursuant to an effective registration statement, (ii) have been sold pursuant to Rule 144 of
the Securities Act, or (iii) are eligible for resale under Rule 144(b)(1) of the Securities Act or any successor provision (such
earliest date, the “Effective Date”), the Company shall, in accordance with the provisions of this Section
4.6(b) and within two (2) Business Days of any request therefor from a Purchaser accompanied by such customary and reasonably
acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent
shall make a new, unlegended entry for such book entry Shares, and (B) cause its counsel to deliver to the Transfer Agent
one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities
Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement.
The Company agrees that following the Effective Date or at such time as such legend is no longer required under this Section
4.6, it will, within two (2) Business Days of the delivery by a Purchaser to the Company or the Transfer Agent of a certificate
representing shares issued with a restrictive legend and receipt from the Purchaser by the Company and the Transfer Agent of the
customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith
that is referred to above, deliver or cause to be delivered to such Purchaser a certificate representing such Shares (or uncertificated
interest therein) that is free from all restrictive and other legends. Shares subject to legend removal hereunder may be transmitted
by the Transfer Agent to the Purchaser by crediting the account of the Purchaser’s prime broker with The Depository Trust
Company as directed by such Purchaser. The Company shall be responsible for the fees of its Transfer Agent and all fees of The
Depository Trust Company associated with such issuance.

 

    17

     

    

 

Section 4.7          
Indemnification.

 

(a)           Indemnification by the Company. The Company will indemnify and hold harmless each Purchaser and its officers, directors,
members, employees and agents, successors and assigns, and each other person, if any, who controls such Purchaser within the meaning
of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which they may become subject under
the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out
of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material
fact contained in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof;
(ii)  any violation by the Company or its agents of any rule or regulation promulgated under the Securities Act applicable
to the Company or its agents and relating to action or inaction required of the Company in connection with such registration; or
(iii) any failure to register or qualify the Registrable Securities included in any such Registration Statement in any state
where the Company or its agents has affirmatively undertaken or agreed in writing that the Company will undertake such registration
or qualification on a Purchaser’s behalf and will reimburse such Purchaser, and each such officer, director or member and
each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any
such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon (i) an untrue statement
or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Purchaser
or any such controlling person in writing specifically for use in such Registration Statement or Prospectus, (ii) the use by a
Purchaser of an outdated or defective Prospectus after the Company has notified such Purchaser in writing that such Prospectus
is outdated or defective, (iii) a Purchaser’s failure to send or give a copy of the Prospectus or supplement (as then amended
or supplemented), if required (and not exempted) to the Persons asserting an untrue statement or omission or alleged untrue statement
or omission at or prior to the written confirmation of the sale of Registrable Securities or (iv) the disposition of any Registrable
Securities pursuant to any Registration Statement or Prospectus covering such Registrable Securities following delivery of notice
by the Company in accordance with Section 4.2(c) and prior to being advised by the Company that such dispositions may
again be made.

 

(b)           Indemnification by the Purchasers. Each Purchaser agrees, severally but not jointly, to indemnify and hold harmless,
to the fullest extent permitted by law, the Company, its directors, officers, employees, agents, stockholders and each person who
controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses (including
reasonable attorney fees) resulting from any untrue statement of a material fact or any omission of a material fact required to
be stated in any Registration Statement or Prospectus or preliminary Prospectus or any amendment or supplement to any of the foregoing
or necessary to make the statements in any of the foregoing not misleading, to the extent, but only to the extent that such untrue
statement or omission is contained in any information furnished in writing by such Purchaser to the Company specifically for inclusion
in such Registration Statement or Prospectus or amendment or supplement thereto. Except to the extent that any such losses, claims,
damages, liabilities or expenses are finally judicially determined to have resulted from a Purchaser’s fraud or willful misconduct,
in no event shall the liability of such Purchaser pursuant to this Section 4.7(b) be greater in amount than the dollar
amount of the proceeds (net of the amount of any damages such Purchaser has otherwise been required to pay by reason of such untrue
statement or omission) received by such Purchaser upon the sale of the Registrable Securities included in such Registration Statement
giving rise to such indemnification obligation.

 

    18

     

    

 

(c)           Conduct of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt
notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any
person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense
of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying
party has agreed to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such
claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based
upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to
such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate
counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such
claim on behalf of such person); and provided, further, that the failure of any indemnified party to give notice as provided
herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice
shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that
the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of
more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with
the consent of the indemnified party, which shall not be unreasonably withheld or conditioned or delayed, consent to entry of any
judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff
to such indemnified party of a release from all liability in respect of such claim or litigation.

 

(d)           Contribution. If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is
unavailable to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying
party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability
in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well
as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f)
of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. Except
to the extent that any such losses, claims, damages, liabilities or expenses are finally judicially determined to have resulted
from a Purchaser’s fraud or willful misconduct, in no event shall the contribution obligation of a Purchaser’s pursuant
to this Section 4.7(d) be greater in amount than the dollar amount of the proceeds (net of the amount of any damages
such Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by such Purchaser upon the sale of the Registrable Securities giving rise to such contribution obligation.

 

    19

     

    

 

Section 4.8          
Amendment and Waiver. Any term of this Article 4 may be amended and the observance of any term of this Article
4 may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written
consent of the Company and the holders of a majority of the Registrable Securities then held by the Purchasers or Permitted Transferees.

 

ARTICLE 5

CONDITIONS OF PURCHASE OF THE SHARES

 

Section 5.1          
Conditions to the Sale of the Shares. The obligation of the Company to issue and sell Shares to each Purchaser shall
be subject to the fulfillment of the following conditions unless such condition or conditions are otherwise waived by the Company:

 

(a)           The Company shall have received executed counterparts of this Agreement from each Purchaser;

 

(b)          Such Purchaser shall have delivered the purchase price for the Shares set forth opposite such Purchaser’s name on
Schedule 1 hereto to the Company in accordance with this Agreement;

 

(c)           The representations and warranties made by such Purchaser in Section 3.2 hereof shall be true and correct as of the
Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which
case such representations and warranties shall be true and correct as of such date;

 

(d)          Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by it at or prior to Closing;

 

(e)           The Company shall have received a Form W-9 or W-8BEN or W-8BEN-E executed by such Purchaser; and

 

(f)           Such Purchaser shall have executed and delivered an Investor Questionnaire that is reasonably satisfactory to the Company.

 

Section 5.2          
Conditions to the Purchase of the Shares. The obligation of each Purchaser to purchase Shares shall be subject to the
fulfillment of the following conditions unless such condition or conditions are otherwise waived by such Purchaser:

 

(a)           Such Purchaser shall have received executed counterparts of this Agreement from the Company;

 

(b)          The representations and warranties made by the Company in Section 3.1 hereof shall be true and correct as of the
Closing Date, except to the extent such representations and warranties are specifically made as of a particular date, in which
case such representations and warranties shall be true and correct as of such date;

 

    20

     

    

 

 

(c)         
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by it at or prior to Closing;

 

(d)         
The Company shall have delivered a certificate of the Secretary or Assistant Secretary of the Company, certifying as to
(1) the Organizational Documents, and (2) board resolutions authorizing the execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby;

 

(e)         
The Company shall have filed with The Nasdaq Global Select Market a Notification Form: Listing of Additional Shares for
the listing of the Shares, and The Nasdaq Global Select Market shall have raised no objection to the consummation of the transactions
contemplated by this Agreement;

 

(f)          
The Company shall have delivered to the Purchasers the opinion of Wilmer Cutler Pickering Hale and Dorr LLP, outside counsel
for the Company, dated as of the Closing Date in substantially the form attached hereto as Exhibit A; and

 

(g)         
The Company shall have completed the Public Offering.

 

Section 5.3          
Mutual Conditions to Closing. The obligation of the Company to issue and sell Shares to each Purchaser and the obligation
of each Purchaser to purchase Shares shall be subject to the fulfillment of the following conditions unless such condition or conditions
are otherwise mutually waived by the Parties:

 

(a)         
There shall be no action, suit, proceeding or investigation by a Governmental Authority pending or currently threatened
in writing against the Company (to the Knowledge of the Company) or the Purchasers that questions the validity of any of this Agreement,
the right of the Company or the Purchasers to enter into this Agreement or to consummate the transactions contemplated hereby;
and

 

(b)         
No provision of any Applicable Law, and no judgment, injunction (whether preliminary or permanent), order or decree, that
prohibits, makes illegal or enjoins the consummation of the transactions contemplated by this Agreement, shall be in effect.

 

ARTICLE 6

 

MISCELLANEOUS

 

Section 6.1          
Notices. Any notices required or permitted to be given under the terms hereof shall be sent by electronic mail and deemed
given if received during normal business hours of the recipient on a Business Day, or if not so received, on the next Business
Day. All notices shall be addressed to the Party to be notified at the address as follows, or at such other address as such Party
may designate by giving the other Party written notice thereof in accordance with the terms of this Section 6.1:

 

    21

     

    

 

If to the Company:

 

IVERIC bio, Inc.

One Penn Plaza, 35th Floor

New York, New York 10119

Attention: General Counsel

Email: notices@ivericbio.com

 

With a copy to:

 

Wilmer Cutler Pickering Hale and Dorr LLP

Attn: Brian A. Johnson, Esq.

Email: brian.johnson@wilmerhale.com

 

If to the Purchasers: To the electronic
mail address set forth immediately below such Purchaser’s name on the signature pages hereto.

 

Section 6.2          
Waiver of Notice. Whenever any notice is required to be given to any of the Purchasers or the Company under this Agreement,
a waiver thereof in writing signed by the Person or Persons entitled to such notice, whether before or after the time stated therein,
shall be deemed equivalent to the giving of such notice.

 

Section 6.3          
Amendment and Waiver. Subject to Section 4.8, any term of this Agreement may be amended and the observance of
any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively)
only with the written consent of the Company and the Purchasers (or their Permitted Transferees) holding Shares representing more
than 50% of the Shares outstanding or, if prior to the Closing, to be purchased by the Purchasers pursuant to this Agreement.

 

Section 6.4          
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement
and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the
State of New York without regard to the choice of law principles thereof. Each Party agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a Party
hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in
the state and federal courts sitting in the City of New York. Each Party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or other proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each Party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or other proceeding by mailing
a copy thereof via registered or certified United States mail or overnight delivery (with evidence of delivery) to such Party at
its address under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law, including via electronic mail and the Parties agree that if service by process by electronic mail is permitted by law,
then the electronic mail addresses in effect for notices to it under this Agreement may be used for such purposes. The
Parties hereby waive all rights to a trial by jury.

 

    22

     

    

 

Section
6.5          
Successors and Assigns; No Third Party Beneficiaries. This Agreement shall bind and inure to the respective
successors and assigns of the Parties. None of the parties hereto may assign its rights or obligations hereof without the prior
written consent of the Company, except that a Purchaser may, without the prior consent of the Company, assign its rights to purchase
the Shares hereunder to a Permitted Transferee (provided each such Permitted Transferee provides written notice of assignment to
the Company promptly after such assignee is effected and such assignee agrees in writing to be bound by the terms of this Agreement
and makes the same representations and warranties set forth in Section 3.2 hereof). Notwithstanding the foregoing, a Purchaser
may only transfer or assign without the prior consent of the Company, in whole or from time to time in part, to one or more Permitted
Transferees its rights under Article 4 in connection with the transfer of Registrable Securities by such Purchaser to such
Permitted Transferee, provided that (i) such Purchaser complies with all laws applicable thereto and the provisions of this Agreement,
(ii) such transfer may otherwise be effected in accordance with applicable securities laws; (iii) such Purchaser gives prior written
notice to the Company at least ten (10) days prior to the transfer, including the name and address of such Permitted Transferee
and the securities with respect to which such rights are being transferred; and such Permitted Transferee agrees in writing to
be bound by the terms and provisions of this Agreement and following such transfer, the further disposition of such securities
by the Permitted Transferee is subject to the same restrictions set forth in this Agreement, the Securities Act and applicable
state securities laws and (iv) such transfer is otherwise in compliance with this Agreement. Except as specifically provided by
this Section 6.5, the rights of a Purchaser as set out in Article 4 shall not be transferable to any other person
and no person who acquires Shares from a Purchaser shall have the benefit of any of the rights provided under Article 4
of this Agreement, and any attempted transfer by any Purchaser other than as expressly set forth in this Section 6.5 shall
cause all rights of such Purchaser therein to be forfeited. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations,
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. This Agreement is intended
for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor
may any provision hereof be enforced by, any other person, except that the Placement Agents are third party beneficiaries of the
representations and warranties of each Purchaser and the Company set forth herein.

 

Section 6.6          
Entire Agreement. This Agreement contains the entire understanding of the Parties with respect to the matters covered
thereby and supersede any and all other written and oral communications, negotiations, commitments, understandings and writings
with respect thereto.

 

Section 6.7          
Severability. Any provision of this Agreement that is invalid, illegal, prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality, prohibition or unenforceability without
invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum
extent permitted by applicable law, and any such invalidity, illegality, prohibition or unenforceability in any jurisdiction shall
not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the
Parties hereby waive any provision of law which renders any provisions hereof invalid, illegal, prohibited or unenforceable in
any respect.

 

    23

     

    

 

Section 6.8          
Counterparts. This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each
of which and any photocopies or other electronic transmission (including by PDF) thereof shall be deemed an original, but all of
which together shall constitute one and the same agreement.

 

Section 6.9          
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement.

 

Section 6.10       
Survival. This Agreement and all agreements, representations and warranties made in this Agreement, and in any document,
certificate or statement delivered pursuant thereto or in connection therewith shall be considered to have been relied upon by
the other Parties and shall survive the execution and delivery of this Agreement and the purchase of the Shares hereunder regardless
of any investigation made by any such other Party or on its behalf. Notwithstanding the foregoing, the warranties and representations
of the Company herein shall survive only for the one-year period following the Closing.

 

Section 6.11       
No Waiver. Neither the failure of, nor any delay on the part of, any Party in exercising any right, power or privilege
under this Agreement, shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege
under this Agreement preclude other or further exercise thereof or the exercise of any other right, power or privilege; nor shall
any waiver of any right, power, privilege or default under this Agreement constitute a waiver of any other right, power, privilege
or default under this Agreement. No course of dealing and no delay in exercising, or omission to exercise, any right, power or
remedy accruing to the Purchasers upon any default under this Agreement shall impair any such right, power or remedy or be construed
to be a waiver thereof or an acquiescence therein; nor shall the action of the Purchasers in respect of any such default, or any
acquiescence by any of them therein, affect or impair any right, power or remedy of the Purchasers in respect of any other default.
All rights and remedies herein provided are cumulative and not exclusive of any rights or remedies otherwise provided by law.

 

Section 6.12       
Several Obligations. The obligations of the Purchasers under this Agreement shall be several and not joint.

 

Section 6.13       
Expenses. Each Party shall pay its own fees and expenses in connection with the preparation, negotiation, execution
and delivery of this Agreement.

 

Section 6.14       
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery
of damages, each of the Purchasers and the Company will be entitled to specific performance under this Agreement. The parties agree
that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained herein
and hereby agree to waive and not to assert in any action or proceeding for specific performance of any such obligation the defense
that a remedy at law would be adequate.

 

    24

     

    

 

Section 6.15       
Further Assurances. From time to time, each Party shall perform any and all acts and execute and deliver to the other
Parties all such additional instruments and documents and take all such other actions as may be necessary or as reasonably requested
by another Party to carry out the purposes of this Agreement, to evidence the fulfillment of the agreements herein contained, or
to preserve and protect the rights of such other Party as contemplated herein and therein.

 

Section 6.16       
Securities Laws Disclosure; Publicity. The Company shall: (a) issue a press release disclosing the material terms of
the transactions contemplated hereby promptly following the execution and delivery hereof (the “Press Release”),
and (b) by 5:30 p.m. (New York City time) on the fourth Trading Day following the date hereof, file a Current Report on Form 8-K
disclosing the material terms of the transactions contemplated hereby which shall have been previously reviewed by the Purchasers
(the “Form 8-K”). From and after the issuance of the Press Release, no Purchaser shall be in possession of any
material, non-public information received from the Company or any of their respective officers, directors or employees that is
not disclosed in the SEC Reports and the Press Release.

 

Section 6.17       
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by
this Agreement and the Public Offering (collectively, “Non-Public Information”), the Company covenants and agrees
that neither it nor any other person acting on its behalf will provide any Purchaser or its agents or counsel with any information
that the Company believes constitutes material non-public information.

 

[Signature Page Follows]

 

    25

     

    

 

IN WITNESS WHEREOF, the Purchasers and the
Company have caused this Agreement to be duly executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	IVERIC BIO, INC.
	 	 
	 	By:	/s/ David F. Carroll
	 	Name:   	David F. Carroll
	 	Title: 	SVP/CFO/Treasurer

 

[Stock Purchase Agreement]

 

     

     

    

 

	 	PURCHASERS:
	 	 
	 	SAMSARA BIOCAPITAL, L.P.
	 	 	 
	 	By:	Samsara BioCapital GP, LLC,
	 	 	General Partner
	 	 	 
	 	By:   	/s/ Srinivas Akkaraju
	 	 	Name: Srinivas Akkaraju, MD, PhD
	 	 	Title: Managing Member
	 	 	Address:
	 	 	Email:

  

[2020 PIPE – Stock Purchase Agreement]

 

     

     

    

 

	 	PURCHASERS:
	 	 
	 	Vivo Capital Fund IX, L.P.
	 	 	 
	 	By:	Vivo Capital IX, LLC
	 	 	 
	 	By:	/s/ Albert Cha
	 	 	Name: Albert Cha
	 	 	Title: Managing Member
	 	 	Address:
	 	 	Email:

 

[2020 PIPE – Stock Purchase Agreement]

 

     

     

    

 

	 	PURCHASERS:
	 	 
	 	Vivo Opportunity Fund,
    L.P.
	 	 
	 	By:	Vivo Opportunity, LLC
	 	 
	 	By:	/s/ Albert Cha
	 	Name: Albert Cha
	 	Title: Managing Member
	 	Address:
	 	Email:

 

[2020 PIPE – Stock Purchase Agreement]

 

     

     

    

 

SCHEDULE 1

 

	PURCHASER	PURCHASE PRICE
	Samsara BioCapital, L.P.	$11,000,000
	Vivo Capital Fund IX, L.P.	$4,462,767
	Vivo Opportunity Fund, L.P.	$20,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]